摘要
目的:探讨粪便SFRP 2基因甲基化联合定量免疫便潜血检测对结直肠癌筛查的临床意义.方法:选择2018年01月至2018年12月在消化科门诊行结肠镜检查的106例结直肠癌、106例进展性腺瘤和106例肠镜正常者,留取粪便标本,同时进行甲基化特异性PCR检测粪便SFRP2基因启动子甲基化和定量免疫便潜血检测,计算阳性率、敏感性和特异性.结果:粪便SFRP 2基因甲基化和定量免疫便潜血在结直肠癌组、进展性腺瘤组和肠镜正常组阳性率分别为77.35%,25.47%,6.60%;83.96%,15.09%和1.87%,结直肠癌组和进展性腺瘤组均高于对照组(P<0.05),结直肠癌组高于进展性腺瘤组(P<0.05).SFRP2甲基化联合定量免疫便潜血在结直肠癌组、进展性腺瘤组和对照组中分别为91.51%,52.83%和5.66%,结直肠癌组、进展性腺瘤组分别高于单独检测阳性检出率(P<0.05).粪便中SFRP2基因甲基化,定量免疫便潜血以及联合检测的灵敏性分别为77.35%,83.96%和93.40%,特异性分别为93.40%,98.11%和93.40%.联合检测灵敏性高于单独检测(P<0.05).结论:SFRP2甲基化联合定量免疫便潜血可以提高筛查结直肠癌准确性,具有潜在临床价值.
Objective:To investigate the clinical significance of SFRP2 gene methylation combined with quantitative immunochemical fecal occult blood test for colorectal cancer screening.Methods:106 patients with colorectal cancer,106 patients with advanced adenoma and 106 healthy people who underwent colonoscopy and pathology in the hospital's gastroenterology clinic were selected.Fecal samples were collected for Methylation-specific PCR to detect the methylation of fecal SFRP2 gene promoter and quantitative immunochemical fecal occult blood.Positive rate was calculated.Results:The positive rate of fecal SFRP2 gene methylation and positive QFIT were 77.35%,25.47%,6.60%,83.96%,15.09%,1.87%in the colorectal cancer group,advanced adenoma group and control group,respectively.The cancer group and the advanced adenoma group were higher than the control group(P<0.05),and the colorectal cancer group was higher than the advanced adenoma group(P<0.05).The positive rate of SFRP2 methylation combined with QFIT was 91.51%,52.83%and 5.66%in the colorectal cancer group,advanced adenoma group and control group,respectively.The detection rate of colorectal cancer group and the advanced adenoma group were higher than the individual test.(P<0.05).SFRP2 gene methylation in feces,the sensitivity of fecal occult blood quantification and combined detection were 77.35%,83.96%and 93.40%,respectively,and the specificities were 93.40%,98.11%and 93.40%,respectively.The sensitivity of the combined detection were higher than individual test(P<0.05).Conclusion:SFRP2 methylation combined with fecal occult blood quantification could improve the accuracy of screening colorectal cancer and have potential clinical value.
作者
康倩
谢惠
王昕
张杰
李娜
盛剑秋
KANG Qian;XIE Hui;WANG Xin(The Seventh Medical Center of PLA General Hospital,Beijing 100700,China)
出处
《河北医学》
CAS
2020年第7期1097-1100,共4页
Hebei Medicine
基金
北京市科技计划课题,(编号:D171100002617001)。
关键词
SFRP2
甲基化
定量免疫便潜血
结直肠癌
SFRP2
Methylation
Quantitative immunochemical fecal occult blood test
Colorectal cancer
